Clinical significance of serum and urinary interleukin-6 in systemic lupus erythematosus patients

Previous studies reported higher interleukin-6 (IL-6) levels in systemic lupus erythematosus (SLE) patients than in healthy controls. However, the clinical relevance of IL-6 in SLE has not been clearly established. The present study aimed to evaluate the clinical significance of serum and urinary IL...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian rheumatologist 2017-01, Vol.39 (1), p.1-6
Main Authors: Dima, A., Jurcut, C., Balanescu, P., Balanescu, E., Badea, C., Caraiola, S., Miler, I., Ramba, D., Ionescu, R., Baicus, C., Dan, G.A., Mircescu, G.
Format: Article
Language:English
Subjects:
Hydroxychloroquine
Interleukin-6
SLAM
Systemic lupus erythematosus
Urinary biomarker
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies reported higher interleukin-6 (IL-6) levels in systemic lupus erythematosus (SLE) patients than in healthy controls. However, the clinical relevance of IL-6 in SLE has not been clearly established. The present study aimed to evaluate the clinical significance of serum and urinary IL-6 and their usefulness as markers of disease activity in SLE. 63 SLE patients were included. Disease activity was assessed according to the Systemic Lupus Activity Measure (SLAM) score. Serum and urinary IL-6 were assessed by ELISA. The study included 63 Romanian patients, female to male ratio 9.5:1 with a mean age of 45.4±12.6years and disease duration of 8 (3–12.3) years. The median SLAM score at inclusion was 5 (range 3–8). Urinary IL-6 significantly correlated with proteinuria (r=0.25; p=0.04) and negatively with the platelet count, C3 and C4 levels (r=−0.38; p=0.002, r=−0.43; p=0.001, and r=−0.46; p
ISSN:1110-1164
2090-2433
DOI:10.1016/j.ejr.2016.05.005